232 related articles for article (PubMed ID: 30966822)
21. Mechanisms and prediction of short-term natriuretic effect of sodium-glucose cotransporter 2 inhibitor in heart failure patients coexisting type 2 diabetes mellitus.
Fukuoka S; Dohi K; Takeuchi T; Moriwaki K; Ishiyama M; Omori T; Fujimoto N; Ito M
Heart Vessels; 2020 Sep; 35(9):1218-1226. PubMed ID: 32270357
[TBL] [Abstract][Full Text] [Related]
22. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
[TBL] [Abstract][Full Text] [Related]
23. Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.
Kramer CK; Ye C; Campbell S; Retnakaran R
JACC Heart Fail; 2018 Oct; 6(10):823-830. PubMed ID: 30196071
[TBL] [Abstract][Full Text] [Related]
24. Treatment of heart failure with sodium glucose co-transporter-2 inhibitors in people with type 2 diabetes mellitus: current evidence and future directions.
Sharma A; Butler J; Zieroth S; Giannetti N; Verma S
Diabet Med; 2019 Dec; 36(12):1550-1561. PubMed ID: 31536660
[TBL] [Abstract][Full Text] [Related]
25. Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials.
Giugliano D; Maiorino MI; Longo M; Bellastella G; Chiodini P; Esposito K
Endocrine; 2019 Jul; 65(1):15-24. PubMed ID: 31028667
[TBL] [Abstract][Full Text] [Related]
26. Sodium-glucose co-transporter 2 inhibitors and heart failure-the present and the future.
Nana M; Morgan H; Bondugulapati LNR
Heart Fail Rev; 2021 Jul; 26(4):953-960. PubMed ID: 32020487
[TBL] [Abstract][Full Text] [Related]
27. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
[TBL] [Abstract][Full Text] [Related]
28. Cost-Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Patients With Heart Failure in China: A New Pillar in Our Pockets, but at What Price?
Camilli M; Ballacci F; Giordano F; Minotti G
J Cardiovasc Pharmacol; 2024 Jan; 83(1):43-45. PubMed ID: 37815278
[No Abstract] [Full Text] [Related]
29. SGLT-2 Inhibitors in Heart Failure and Type-2 Diabetes: Hitting Two Birds with One Stone?
Santos-Ferreira D; Gonçalves-Teixeira P; Fontes-Carvalho R
Cardiology; 2020; 145(5):311-320. PubMed ID: 31865310
[TBL] [Abstract][Full Text] [Related]
30. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis.
Usman MS; Siddiqi TJ; Memon MM; Khan MS; Rawasia WF; Talha Ayub M; Sreenivasan J; Golzar Y
Eur J Prev Cardiol; 2018 Mar; 25(5):495-502. PubMed ID: 29372664
[TBL] [Abstract][Full Text] [Related]
31. Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis.
Castellana M; Procino F; Sardone R; Trimboli P; Giannelli G
Cardiovasc Diabetol; 2020 Jun; 19(1):87. PubMed ID: 32534590
[TBL] [Abstract][Full Text] [Related]
32. News from the American Heart Association: more on sodium-glucose co-transporter 2 inhibitors, diabetes and heart failure.
Coats AJS; Seferović PM
Eur J Heart Fail; 2019 Mar; 21(3):261-263. PubMed ID: 30884001
[No Abstract] [Full Text] [Related]
33. Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME.
Verma S; Mazer CD; Al-Omran M; Inzucchi SE; Fitchett D; Hehnke U; George JT; Zinman B
Circulation; 2018 Jan; 137(4):405-407. PubMed ID: 29133602
[No Abstract] [Full Text] [Related]
34. Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled and observational studies.
Singh AK; Singh R
Expert Rev Clin Pharmacol; 2019 Apr; 12(4):299-308. PubMed ID: 30817235
[TBL] [Abstract][Full Text] [Related]
35. Sodium-glucose co-transporter-2 inhibitors and protection from cardiovascular death: Is it all about heart failure?
Caruso I; Cignarelli A; Laviola L; Giorgino F
Diabetes Obes Metab; 2021 Sep; 23(9):2194-2196. PubMed ID: 34033214
[No Abstract] [Full Text] [Related]
36. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials.
Ghosh-Swaby OR; Goodman SG; Leiter LA; Cheng A; Connelly KA; Fitchett D; Jüni P; Farkouh ME; Udell JA
Lancet Diabetes Endocrinol; 2020 May; 8(5):418-435. PubMed ID: 32333878
[TBL] [Abstract][Full Text] [Related]
37. Effect of canagliflozin use on body weight and blood pressure at one-year follow-up: A systematic review and meta-analysis.
Khan MS; Usman MS; Siddiqi TJ; Memon MM; Shah SJ; Khan SS
Eur J Prev Cardiol; 2019 Oct; 26(15):1680-1682. PubMed ID: 30755019
[No Abstract] [Full Text] [Related]
38. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
Mahaffey KW; Neal B; Perkovic V; de Zeeuw D; Fulcher G; Erondu N; Shaw W; Fabbrini E; Sun T; Li Q; Desai M; Matthews DR;
Circulation; 2018 Jan; 137(4):323-334. PubMed ID: 29133604
[TBL] [Abstract][Full Text] [Related]
39. Promise, Innovation, Potency, and Efficacy: The PIPE Dream of Sodium-Glucose Co-Transporter 2 Inhibitors.
Butler J
Am J Cardiol; 2019 Dec; 124 Suppl 1():S1-S2. PubMed ID: 31741434
[No Abstract] [Full Text] [Related]
40. Is composite cardiovascular death or hospitalization for heart failure a valid surrogate for mortality in patients treated with sodium-glucose cotransporter 2 inhibitors? A correlation meta-analysis.
Diallo A; Carlos-Bolumbu M; Galtier F
Diabetes Obes Metab; 2024 Jan; 26(1):392-395. PubMed ID: 37853835
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
